Clinicians now have more tools than ever to assess risk and for clinical diagnosis. A patient’s unique
information is one of these tools that can also be used to assist in diagnosis, contribute to preventative
strategies, and allow for management or therapies to begin at a much earlier stage than ever before.
The Avellino test has been a great diagnostic tool for us. It’s also just the tip of the iceberg of genetic
testing, and I think Avellino Labs is leading that. I can imagine an expansive array of testing that can
help rule out other pathologies that can present around the time of refractive surgery or other eye
The good news is that there are emerging technologies that will allow for CRISPR technology, which may be
able to reverse these changes. Now I can sit down with a patient that tested positive for disease and be
able to say to them that there is good news in the future. It’s likely in their lifetime that we will have a
treatment for Avellino dystrophy. This has implications not only for the patient, but also the patient's
William Wiley, MD
“It’s extremely important in genetic diseases, specifically in the eye, that we have as much diagnostic
capacity as we can have.”
Genetic medicine is the medicine of the future, but in fact, we already have it today. Avellino has been
very successful in screening pathologies of the cornea.
Professor of Ophthalmology, Moorfield’s Eye Hospital, London
AvaGen helps provide proactive answers to achieve eye health goals for your patients. This could
potentially save a patient from future vision loss.
Tailoring medicine with specific, individualized information for patients is — by definition
— precision medicine, and Avellino is leading the way in incorporating precision medicine into
modern eyecare practices.